Yuzo Ikari

Tokyo, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Soluble CD13 in systemic sclerosis: clinical observations and transcriptomic insights from peripheral blood.

Soluble CD13 in systemic sclerosis: clinical observations and transcriptomic insights from peripheral blood.

Journal: Arthritis research & therapy

Published: July 23, 2025

Soluble CD13 is a potential mediator of neutrophil-induced thrombogenic inflammation in SARS-CoV-2 infection.

Soluble CD13 is a potential mediator of neutrophil-induced thrombogenic inflammation in SARS-CoV-2 infection.

Journal: JCI insight

Published: July 19, 2024

Melanoma Differentiation-associated Gene 5-Positive Rapidly Progressive Interstitial Lung Disease Successfully Treated with Tofacitinib.

Melanoma Differentiation-associated Gene 5-Positive Rapidly Progressive Interstitial Lung Disease Successfully Treated with Tofacitinib.

Journal: Internal medicine (Tokyo, Japan)

Published: July 10, 2024

Targeting CD13/Aminopeptidase N as a Novel Therapeutic Approach for Scleroderma Fibrosis.

Targeting CD13/Aminopeptidase N as a Novel Therapeutic Approach for Scleroderma Fibrosis.

Journal: Arthritis & rheumatology (Hoboken, N.J.)

Published: January 19, 2024

Activation of Cytotoxic Lymphocytes Through CD6 Enhances Killing of Cancer Cells.

Activation of Cytotoxic Lymphocytes Through CD6 Enhances Killing of Cancer Cells.

Journal: Research square

Published: October 27, 2023

Activation of cytotoxic lymphocytes through CD6 enhances killing of cancer cells.

Activation of cytotoxic lymphocytes through CD6 enhances killing of cancer cells.

Journal: Cancer immunology, immunotherapy : CII

Published: October 02, 2023

The association between age and adverse events due to biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: A retrospective cohort study.

The association between age and adverse events due to biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: A retrospective cohort study.

Journal: Medicine

Published: May 08, 2020

Peficitinib Inhibits the Chemotactic Activity of Monocytes via Proinflammatory Cytokine Production in Rheumatoid Arthritis Fibroblast-Like Synoviocytes.

Peficitinib Inhibits the Chemotactic Activity of Monocytes via Proinflammatory Cytokine Production in Rheumatoid Arthritis Fibroblast-Like Synoviocytes.

Journal: Cells

Published: May 22, 2019

A study on characteristics of rheumatoid arthritis patients achieving remission in depression with 6 months of bDMARDs treatment.

A study on characteristics of rheumatoid arthritis patients achieving remission in depression with 6 months of bDMARDs treatment.

Journal: European journal of rheumatology

Published: August 26, 2017

Clinical Characteristics of Rheumatoid Arthritis Patients Achieving Functional Remission after Six Months of Non-tumor Necrosis Factor Biological Disease-Modifying Antirheumatic Drugs (DMARDs) Treatment.

Clinical Characteristics of Rheumatoid Arthritis Patients Achieving Functional Remission after Six Months of Non-tumor Necrosis Factor Biological Disease-Modifying Antirheumatic Drugs (DMARDs) Treatment.

Journal: Internal medicine (Tokyo, Japan)

Published: August 11, 2017

Clinical Characteristics of Rheumatoid Arthritis Patients Achieving Functional Remission with Six Months of Biological DMARDs Treatment.

Clinical Characteristics of Rheumatoid Arthritis Patients Achieving Functional Remission with Six Months of Biological DMARDs Treatment.

Journal: Internal medicine (Tokyo, Japan)

Published: April 20, 2017

Comparative Study of Infliximab Therapy and Methotrexate Monotherapy to Improve the Clinical Effect in Rheumatoid Arthritis Patients.

Comparative Study of Infliximab Therapy and Methotrexate Monotherapy to Improve the Clinical Effect in Rheumatoid Arthritis Patients.

Journal: Internal medicine (Tokyo, Japan)

Published: September 16, 2016

Showing 1-12 of 12

Last Updated: 09/26/2026